Disc Medicine to Present Promising Phase 2 Data for DISC-0974 in Myelofibrosis at ASCO

Event summary

  • Disc Medicine will present Phase 2 trial data for DISC-0974 in myelofibrosis anemia at ASCO on June 2, 2026.
  • Initial RALLY-MF trial data showed unprecedented anemia response rates in hard-to-treat myelofibrosis patients.
  • Abstract #6501 details the efficacy of DISC-0974, an anti-hemojuvelin antibody, in treating anemia of myelofibrosis.
  • Presentation will include additional data from patients receiving transfusions.

The big picture

Disc Medicine's presentation at ASCO highlights the potential of DISC-0974 to address a critical unmet need in myelofibrosis patients with anemia. The focus on heme biosynthesis and iron homeostasis aligns with broader industry trends toward targeted therapies in hematologic diseases. The success of this trial could position Disc Medicine as a key player in the hematology space, particularly if the data translates into long-term clinical benefits.

What we're watching

Clinical Efficacy
How the unprecedented anemia response rates will position DISC-0974 against existing treatments.
Regulatory Pathway
The pace at which Disc Medicine can advance DISC-0974 through subsequent clinical trials and potential approval.
Market Differentiation
Whether DISC-0974 can sustain its efficacy in larger, more diverse patient populations.